Company Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
4.8 ^USD	-6.07%		+18.23%	+13.74%

Apr. 22	Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	MT
Apr. 22	U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents	RE

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Number of employees: 203

USD in Million	2022	Weight	2023	Weight	Delta
Therapies 100.0 %	254	100.0 %	193	100.0 %	-24.27%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	254	100.0 %	193	100.0 %	-24.27%

Managers	Title	Age	Since
Mihael Polymeropoulos CEO	Chief Executive Officer	64	02-10-31
Kevin Moran DFI	Director of Finance/CFO	40	12-11-30
Scott Howell HRO	Human Resources Officer	-	19-07-31
Kim Wijkstrom SAM	Sales & Marketing	57	19-08-20
Tim Williams LAW	General Counsel	48	18-08-12
Gunther Birznieks PRN	Corporate Officer/Principal	55	03-05-31
Deepak Shripad Phadke PRN	Corporate Officer/Principal	73	05-07-31

Members of the board	Title	Age	Since
Richard W. Dugan BRD	Director/Board Member	82	05-11-30
Mihael Polymeropoulos CEO	Chief Executive Officer	64	02-10-31
Stephen Ray Mitchell BRD	Director/Board Member	72	20-02-13
Anne Sempowski Ward BRD	Director/Board Member	52	19-10-27
Phaedra Chrousos BRD	Director/Board Member	44	19-04-23
Tage Honoré BRD	Director/Board Member	-	23-03-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	57,537,499	54,541,643 ( 94.79 %)	0	94.79 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 13.19 %	7,589,716	13.19 %	31 M $
Renaissance Technologies LLC 6.398 %	3,681,125	6.398 %	15 M $
Vanguard Fiduciary Trust Co. 6.007 %	3,456,087	6.007 %	14 M $
Acadian Asset Management LLC 3.933 %	2,263,132	3.933 %	9 M $
D.E. Shaw & Co., Inc. 3.671 %	2,112,125	3.671 %	9 M $
Morgan Stanley Investment Management, Inc. 3.516 %	2,022,968	3.516 %	8 M $
Dimensional Fund Advisors LP 3.420 %	1,967,985	3.420 %	8 M $
Pictet Asset Management Holding SA 3.335 %	1,919,002	3.335 %	8 M $
Mihael Polymeropoulos 3.253 %	1,871,730	3.253 %	8 M $
Assenagon Asset Management SA 2.759 %	1,587,717	2.759 %	7 M $

Vanda Pharmaceuticals, Inc.

2200 Pennsylvania Avenue NW Suite 300E

20037, Washington

+202 734 3400

http://www.vandapharma.com

address Vanda Pharmaceuticals Inc.(VNDA)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VANDA PHARMACEUTICALS INC.	+13.74%	276M
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
ARGENX SE	-0.26%	21.31B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-5.29%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-27.40%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B
LEGEND BIOTECH CORPORATION	-21.79%	8.56B

Bio Therapeutic Drugs